Arrowhead Pharmaceuticals (ARWR) FY2015 results: revenue $382,000, up 118.3% on the year
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $382,000 for fiscal 2015, the year ended 30 September 2015, up 118.3% on the year before. Net income was -$92 million, and diluted earnings per share $-1.60. The figures are the company's own, from the 10-K it filed with the SEC on 14 December 2015.
Revenue
$382,000
+118.3% on the year
FY2011FY2015
Operating margin
-25124.1%
-30443.6% a year earlier
FY2011FY2015
Net income
-$92 million
FY2011FY2015
Diluted EPS
-$1.60
FY2011FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
0.4
0.2
0.3
+118.3%
Research and development
47.3
23.1
8.7
+104.3%
Operating income
-96.0
-53.3
-24.6
Operating margin
-25124.1%
-30443.6%
-8471.3%
Pre-tax income
-91.9
-58.7
-31.7
Income tax
0.0
0.0
n/a
-54.7%
Net income
-91.9
-58.6
-31.1
Net margin
-24068.3%
-33503.0%
-10729.2%
Diluted EPS
-$1.60
-$1.25
-$1.30
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
-65.7
-35.4
-19.0
Capital expenditure
2.0
1.7
0.3
+14.7%
Free cash flow
-67.7
-37.1
-19.3
Free cash flow margin
-17716.8%
-21219.3%
-6659.4%
Depreciation and amortisation
2.3
1.3
1.8
+73.6%
Share-based compensation
10.2
5.7
1.5
+79.6%
Shares outstanding at period end
60m
55m
32m
+8.9%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
110
167
27.5
-33.8%
Non-controlling interest
-0.6
-0.6
-1.8
Debt
0.0
0.1
0.1
Other liabilities
22.6
16.8
11.5
+34.9%
Total liabilities and equity
132
183
37.3
-27.7%
Fixed assets
4.5
3.9
3.5
+16.9%
Intangible assets
24.8
1.0
3.2
+2,349.4%
Investments
n/a
44.7
10.7
Securities held for sale or to maturity
17.5
n/a
n/a
Cash and equivalents
81.2
133
19.1
-38.7%
Receivables
n/a
n/a
0.1
Other assets
4.2
0.7
0.7
+513.5%
Total assets
132
183
37.3
-27.7%
10-K for the year ended 30 September 2015, filed 14 December 2015: the filing.